Fully human bi- and multi-specific antibodies for the treatment of Alzheimer’s Disease, Neuroinflammation and Antimicrobial Resistant infections
The pipeline of the discoveric bio group comprises three different bi-/multi-specific antibodies currently at discovery stage.
discoveric bio alpha
Program
Targets
Discovery
Preclinical
Clinical
NIDB-3101
Undisclosed
Status:
Lead optimisation phase
Ownership:
discoveric bio group
Format:
κλ body
Indications:
Alzheimer’s disease
Additional info:
discoveric bio beta
Program
Targets
Discovery
Preclinical
Clinical
NIDB-3001
Gram-negative outer membrane proteins
Status:
Discovery
Ownership:
discoveric bio group
Format:
κλ body
Indications:
Gram-negative bloodstream infections
Additional info:
NIDB-3001 is a fully human κλ IgG antibody that interferes with essential Gram-negative outer membrane processes, thereby inhibiting bacterial growth independent of host effector functions.
NIDB-3002
Gram-negative outer membrane proteins
Status:
Discovery
Ownership:
discoveric bio group
Format:
κλ body
Indications:
Gram-negative lung infections
Additional info:
NIDB-3002 is a fully human κλ IgG antibody that interferes with essential Gram-negative outer membrane processes, thereby inhibiting bacterial growth independent of host effector functions.
discoveric bio gamma
Program
Targets
Discovery
Preclinical
Clinical
NIDB-3601
Undisclosed
Status:
Target identification phase
Ownership:
discoveric bio group
Format:
κλ body
Indications:
neuroinflammation
